Author: Halazy S. Lamothe M. Jorand-Lebrun C.
Publisher: Informa Healthcare
ISSN: 1354-3776
Source: Expert Opinion on Therapeutic Patents, Vol.7, Iss.4, 1997-04, pp. : 339-352
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
The molecular pharmacology, functional role and behavioural implications of central 5-HT1B/1D receptors suggest that these particular receptor subtypes probably play an important role in brain serotonin neurotransmission. This article summarises the rationale for considering 5-HT1B/1D antagonists as potential new, fast-acting antidepressants and describes the development of recent selective potent 5-HT1B/1D antagonists, reviewing both the primary and patent literature.
Related content
5-HT 1B/D Receptor Antagonists
By Pauwels P.J.
General Pharmacology, Vol. 29, Iss. 3, 1997-09 ,pp. :
By De Vries P. Sanchez-Lopez A. Centurion D. Heiligers J.P.C. Saxena P.R. Villalon C.M.
European Journal of Pharmacology, Vol. 362, Iss. 1, 1998-11 ,pp. :